Daxxify

Daxxify has a well-characterized safety profile established across the SAKURA phase 3 clinical program. As with all botulinum toxin products, it carries an FDA Boxed Warning regarding the potential for toxin spread beyond the injection site.

FDA Boxed Warning: Botulinum toxin products, including Daxxify, may spread from the injection site and cause symptoms of botulism, including difficulty swallowing, speaking, or breathing, which can be life-threatening. These symptoms have been reported hours to weeks after injection. The risk is greatest in patients treated for conditions other than cosmetic facial lines. Seek immediate medical attention if these symptoms occur. Daxxify is not interchangeable with other botulinum toxin products.

In the SAKURA glabellar line trials, the most common adverse reactions (≥1%) included:

• Headache — reported in approximately 6% of subjects; generally mild and transient
• Eyelid ptosis (drooping) — reported in approximately 2% of subjects; temporary and resolves as the toxin wears off
• Facial paresis — reported in approximately 1% of subjects
• Injection site reactions — erythema, bruising, and tenderness, typically resolving within 24–72 hours

Serious adverse events were rare. The overall safety profile was comparable to other approved neuromodulators. All treatments at Maison Zolara are performed by our licensed RN clinicians under the clinical oversight of our on-staff Medical Director, and a thorough medical history review is completed prior to every treatment.

Contraindications include: known hypersensitivity to any botulinum toxin product or formulation components; infection at the proposed injection site; and pregnancy or breastfeeding. Patients with neuromuscular disorders (e.g., myasthenia gravis, Lambert-Eaton syndrome) should discuss their history with a qualified provider before treatment.

Daxxify is one of several FDA-approved neuromodulators available at Maison Zolara. The right choice depends on your treatment goals, lifestyle, and how frequently you prefer to schedule appointments. The table below summarizes the key differences.

When comparing options, the primary clinical differentiator for Daxxify is duration. Patients in DeWitt, Mason, and surrounding communities who prefer fewer annual appointments often find the six-month profile appealing. Patients who prefer to start with a shorter-acting product to gauge their response may prefer to begin with one of the alternatives below.

Botox, Dysport, and Xeomin are shorter-acting neuromodulator alternatives, each covered on their own dedicated pages at Maison Zolara. Our licensed RN clinicians can help you compare options during a complimentary consultation.

Daxxify

Best suited for patients who want fewer annual appointments, have an established neuromodulator history, and are comfortable with a longer-acting product. The peptide-stabilized formula and vegan-friendly profile are additional differentiators for patients with specific preferences.

Botox / Dysport / Xeomin

Shorter-acting alternatives (typically 3–4 months) that may suit patients new to neuromodulators, those who prefer to adjust dosing more frequently, or those who want to trial a product before committing to a longer duration. All three are available at Maison Zolara.

Daxxify is appropriate for most healthy adults who want to reduce the appearance of moderate to severe glabellar lines and prefer a longer-lasting result. It is a particularly strong fit for patients who:

Good Candidates

• Are adults with moderate to severe glabellar lines (frown lines)
• Have an established neuromodulator history and know their typical dosing
• Prefer fewer annual appointments (approximately two per year)
• Are interested in a vegan-friendly, albumin-free formulation
• Have realistic expectations and understand results vary individually
• Are in good general health with no contraindicated conditions

Not a Good Fit

• Known hypersensitivity to any botulinum toxin product
• Active infection at or near the proposed injection site
• Pregnancy or breastfeeding
• Neuromuscular disorders (myasthenia gravis, Lambert-Eaton syndrome, ALS) — discuss with your provider
• Patients seeking a "trial" treatment who prefer a shorter-acting product to assess their response first
• Patients with unrealistic expectations about outcome or duration

Daxxify works by the same fundamental mechanism as all botulinum toxin type A neuromodulators: it temporarily blocks acetylcholine release at the neuromuscular junction, preventing the targeted muscle from contracting and allowing overlying skin to smooth. What sets it apart is how long it sustains that effect.

The key innovation is a proprietary stabilizing excipient peptide called RTP004, which replaces the human serum albumin used in older formulations. This peptide-based stabilizer is believed to contribute to the extended duration of action observed in clinical trials — a median of approximately 24 weeks (six months) across the SAKURA 1 and SAKURA 2 phase 3 studies. Because it contains no human- or animal-derived proteins, Daxxify is also notable as a vegan-friendly neuromodulator option.

Onset is typically rapid. According to patient diary data from the SAKURA trials, many patients reported seeing measurable improvement within two days of treatment, with peak effect generally achieved within one to two weeks.

Clinical bottom line: According to pooled data from the SAKURA 1 and SAKURA 2 phase 3 trials published in the Journal of the American Academy of Dermatology, daxibotulinumtoxinA maintained none or mild glabellar line severity for a median of 24 weeks — roughly twice the duration of standard neuromodulators. ↗

Before Your Treatment

Your journey begins with a complimentary consultation with one of our licensed RN clinicians. We review your medical history, discuss your aesthetic goals, assess your facial anatomy and muscle activity, and confirm that Daxxify is appropriate for you. We will explain the dosing approach, expected duration, and what to do if you have any questions after your appointment. Patients from Holt, Grand Ledge, Williamston, and St. Johns are welcome — our west Lansing location on W Saginaw Hwy is easily accessible from across the mid-Michigan region.

During Treatment

The appointment itself is brief — typically 15 to 30 minutes. After cleansing the treatment area, your RN clinician will administer a series of small injections using a fine-gauge needle. Most patients describe the sensation as a mild pinch. No anesthesia is required, though a topical numbing cream is available on request. The number of injection points and units used will be determined based on your anatomy and goals, confirmed during your consultation.

After Treatment

You can return to most normal activities immediately. Avoid lying flat, vigorous exercise, and rubbing the treated area for four hours post-treatment. Avoid alcohol and anti-inflammatory medications for 24 hours to minimize bruising risk. Initial results are typically visible within two to three days, with peak effect at one to two weeks. Your RN clinician will schedule a follow-up to assess your response and address any questions.

Proper aftercare helps protect your results and minimize the risk of side effects. The following guidelines apply to the first 24–48 hours after treatment.

Do

• Remain upright for at least four hours after treatment
• Apply a cold compress gently to reduce any swelling or redness
• Stay hydrated and follow your normal skincare routine after 24 hours
• Contact our team if you have any concerns about your results
• Schedule your follow-up appointment as recommended

Avoid

• Lying flat or bending forward for four hours post-treatment
• Rubbing, massaging, or applying pressure to the treated area
• Vigorous exercise or activities that raise core body temperature for 24 hours
• Alcohol consumption for 24 hours (increases bruising risk)
• Blood-thinning supplements (aspirin, fish oil, vitamin E) for 24 hours unless medically necessary

Daxxify at Maison Zolara is priced per unit, reflecting the precision dosing approach used by our licensed RN clinicians.

• Standard pricing: From $15/unit
• Maison Circle member pricing: From $13/unit
• Final unit count and total pricing are confirmed at your consultation, based on your anatomy and treatment goals

According to pooled phase 3 data published in the Journal of the American Academy of Dermatology, the median duration of effect for daxibotulinumtoxinA was 24 weeks — meaning patients may require only two treatments per year compared to three or four with standard neuromodulators. ↗

Because Daxxify typically lasts approximately twice as long as standard neuromodulators, the cost-per-month comparison is often favorable for patients who currently maintain quarterly appointments. Our team is happy to walk through this math during your consultation.

Maison Circle members receive member pricing on Daxxify and can track their treatment journey in the Zolara Care app (available on the App Store).

Daxxify (daxibotulinumtoxinA-lanm) received FDA approval on September 7, 2022, making it the first new neuromodulator approved for glabellar lines in the United States in over a decade. It is manufactured by Revance Therapeutics, Inc.

Peptide-Stabilized Formula

Unlike all other FDA-approved neuromodulators, Daxxify uses the proprietary RTP004 peptide excipient instead of human serum albumin or animal-derived proteins. This formulation is free of human and animal components — a meaningful distinction for patients with specific ethical or dietary preferences.

Extended Duration

The SAKURA phase 3 program enrolled more than 2,700 subjects across approximately 4,200 treatments. The median duration of none or mild glabellar line severity was 24 weeks, with some patients maintaining results at nine months. According to data cited by the FDA, more than 50% of patients had no or minor frown lines at six months.

Rapid Onset

Patient diary data from the SAKURA trials indicate that many subjects reported seeing measurable improvement within two days of injection — a faster perceived onset than is typically reported with onabotulinumtoxinA (Botox), where initial results are generally noted at three to seven days.

Vegan-Friendly

Because RTP004 is a synthetic peptide and the formulation contains no human serum albumin or animal-derived stabilizers, Daxxify is considered the first vegan-friendly neuromodulator option available in the United States.

The concern about looking "frozen" or expressionless is one of the most common questions our team hears from patients considering any neuromodulator — and it is worth addressing directly.

A frozen appearance is the result of over-treatment or imprecise placement, not an inherent property of the product. Daxxify, like any neuromodulator, relaxes the targeted muscle; it does not eliminate all movement. When dosed conservatively and placed precisely by a skilled injector, the result is a softening of dynamic lines while preserving natural facial expression.

Because Daxxify's effects last longer than standard toxins, precise dosing at the outset is especially important. Our licensed RN clinicians take a conservative, anatomy-first approach: we start with the appropriate dose for your muscle mass and facial anatomy, assess your response, and adjust at follow-up if needed. The goal is always a refreshed, natural result — not a static one.

The peptide-stabilized formulation does not change the mechanism of muscle relaxation; it extends the duration of the same targeted effect. Patients who have had natural-looking results with other neuromodulators can expect the same quality of outcome with Daxxify, with the added benefit of fewer annual treatments.

Maison Zolara is located at 4820 W Saginaw Hwy in west Lansing, MI 48917 — conveniently situated on W Saginaw Hwy with easy access from across the mid-Michigan region. We serve patients from Lansing, East Lansing, Okemos, Holt, DeWitt, Grand Ledge, Charlotte, Mason, St. Johns, Williamston, and surrounding communities within a 30-mile radius.

Our clinic hours are 9:00 AM – 7:00 PM Monday through Friday and 9:00 AM – 5:00 PM on Saturday. Free consultations are available — book online or call us to schedule.

1. Bertucci V, Solish N, Kaufman-Janette J, et al. DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). J Am Acad Dermatol. 2020;82(4):838–845. https://pubmed.ncbi.nlm.nih.gov/31609882/

2. U.S. Food and Drug Administration. Daxxify (daxibotulinumtoxinA-lanm) — FDA Approval History. First approved September 7, 2022. https://www.drugs.com/history/daxxify.html

3. Drugs.com. Daxxify (daxibotulinumtoxinA-lanm): Package Insert / Prescribing Information. https://www.drugs.com/pro/daxxify.html

4. Skin Therapy Letter. DaxibotulinumtoxinA-lanm (Daxxify™): A Comprehensive Overview. https://www.skintherapyletter.com/cosmetic-dermatology/daxibotulinumtoxina-lanm-daxxify/

Page Disclaimer: The information on this page is provided for educational purposes only and does not constitute medical advice. Clinical references are sourced from peer-reviewed research and named institutions as cited below. Individual results vary. Consult a qualified healthcare provider before beginning any treatment.

The Medical Director provides clinical oversight of treatments performed at this practice. The Medical Director does not author, review, or endorse website content.

Daxxify® is a registered trademark of Revance Therapeutics, Inc.